COVID-19 Therapeutics Checklist for Shelter and Correctional Settings

Overview

- This resource is intended for community-based facilities that offer congregate living, dining, or programming to people experiencing homelessness, people with temporary or transitional housing needs, or people that are justice-involved or otherwise living in a Department of Corrections (DOC)-licensed facility. Examples include homeless service settings and encampments, jails, prisons, DOC-licensed correctional facilities, juvenile detention centers, domestic violence shelters, youth shelters, transitional housing, permanent supportive housing, unlicensed sober homes, halfway houses, and board and lodges.

- Several medications are authorized for use in treating COVID-19 and are effective at reducing severe health outcomes among people most likely to get very sick from COVID-19.

- COVID-19 medications are available for patients who:
  - Have mild to moderate symptoms,
  - Are not in the hospital,
  - Have had symptoms for fewer than seven days, and
  - Are at high risk for severe illness from COVID-19.

- The Centers for Disease Control and Prevention (CDC) recommends that congregate living facilities assess residents’ risk for severe health outcomes from COVID-19 and ensure timely treatment after infection for those who are eligible for COVID-19 therapeutics.
  - Facilities that do not have a health care provider on site should have a plan for referring residents to offsite care where they can be assessed for eligibility and receive COVID-19 therapeutics when eligible.

- This document outlines steps for accessing COVID-19 therapeutics and includes a list of resources to support high-risk congregate living facilities in helping eligible residents access COVID-19 medications.
# Facility checklist for connecting residents to COVID-19 therapeutics

<table>
<thead>
<tr>
<th>Step</th>
<th>Facility requirements</th>
<th>Considerations</th>
<th>Resources and Guidance</th>
</tr>
</thead>
</table>
| 1. Test resident for COVID-19 | - Access to rapid tests or access to lab-based PCR tests with fast turnaround (<24 hours) | - Consider COVID-19 medications for those who are at high risk for severe illness from COVID-19.  
- Rapid test turnaround is critical – oral antivirals must be administered within 5 days of symptom onset.  
- Patient must have a COVID-19 infection confirmed either by RT-PCR or by antigen testing (not serology).  
- Home test or a picture of a home test result may be acceptable.  
- Patient must have at least one COVID-19 symptom to be eligible for therapeutics. | - Visit CDC: People with Certain Medical Conditions ([www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html](http://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)) for a full list of factors that may put someone at high risk  
- COVID-19 Testing and Case Reporting Resources for Shelter and Correctional Settings ([www.health.state.mn.us/diseases/coronavirus/testing.pdf](http://www.health.state.mn.us/diseases/coronavirus/testing.pdf)) (lab based and rapid tests)  
- Contact Health.R-congregate@state.mn.us for additional support identifying testing resources |
| 2. Assess patient for basic eligibility and interest in therapeutics | - Staff are aware of basic eligibility criteria  
- Staff have educational information to provide to patients about therapeutics | - Staff should be able to explain options in simple language, present risks/EUA, and be prepared to refer to a medical provider if patient is interested and meets basic eligibility criteria, which include:  
- Confirmed COVID-19 infection.  
- At least one COVID-19 symptom.  
- Duration of symptoms is within treatment window (within 5 days of symptom onset).  
- COVID-19 Medications ([www.health.state.mn.us/diseases/coronavirus/meds.html](http://www.health.state.mn.us/diseases/coronavirus/meds.html)) information for patients about different types of COVID-19 medications  
- Antiviral Therapy Resources for Providers: COVID-19 ([www.health.state.mn.us/diseases/coronavirus/hcp/antivirals.html](http://www.health.state.mn.us/diseases/coronavirus/hcp/antivirals.html)) is a compilation of resources for |
<table>
<thead>
<tr>
<th>Step</th>
<th>Facility requirements</th>
<th>Considerations</th>
<th>Resources and Guidance</th>
</tr>
</thead>
</table>
| 3. Refer patient to a medical provider to conduct clinical assessment and prescribe medication | □ Provider on site to assess and prescribe OR staff to identify a provider and coordinate referral  
□ Reliable internet service and electronic devices for telehealth visits | ▪ Refer to providers in the following order if possible:  
▪ Patient’s usual provider if they have one.  
▪ Local provider who can serve as future medical home for patient and follow-up with patient.  
□ Consider timeliness of provider options to ensure that visit occurs within treatment window. | ▪ Find a community health center at [MN Association of Community Health Centers](https://mnachc.org/community-health-centers/find-a-health-center/)  
▪ Resources to Find Low-Cost Health Care or Get Health Insurance ([www.health.state.mn.us/diseases/coronavirus/materials/lowcost.html](http://www.health.state.mn.us/diseases/coronavirus/materials/lowcost.html)) |
| 4. Identify pharmacy to dispense medication | □ Access to a clinic or pharmacy with supply of COVID-19 oral antivirals  
□ Appropriate storage space for storing medication (if storing on site) | ▪ The following facilities have access to COVID-19 therapeutic products through the federal government and/or the state:  
▪ Federal and State designated Test to Treat Sites (provide testing, clinic visit, prescribing, and dispensing under one roof).  
▪ Retail pharmacies participating in the Federal Retail Pharmacy Program (FRPTP).  
▪ HRSA (Health Resources and Services Administration) supported health centers.  
▪ Non FRPTP or HRSA supported facilities may request to be onboarded to receive allocations via the state. | ▪ [Where to Access Oral Antiviral Therapy in Minnesota](http://www.health.state.mn.us/diseases/coronavirus/hcp/medsaccess.html)  
▪ HHS ASPR: COVID-19 Test to Treat Locator ([https://aspr.hhs.gov/TestToTreat/Pages/default.aspx](https://aspr.hhs.gov/TestToTreat/Pages/default.aspx))  
▪ CDC: Pharmacies Participating in the Federal Retail Pharmacy Program ([www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/participating-pharmacies.html](http://www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/participating-pharmacies.html))  
▪ If interested in ordering a supply of therapeutics to dispense at your facility, submit the following forms: |
<table>
<thead>
<tr>
<th>Step</th>
<th>Facility requirements</th>
<th>Considerations</th>
<th>Resources and Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>For facilities that do not have an HPOP account:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Oral Antivirals Interest Survey  [<a href="https://redcap.health.state.mn.us/redcap/surveys/?s=C4F78MFMMN43E74WY">https://redcap.health.state.mn.us/redcap/surveys/?s=C4F78MFMMN43E74WY</a>] (Paxlovid, renal packaged Paxlovid and/or Molnupiravir)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Therapeutic Evusheld Interest Survey  [<a href="https://redcap.health.state.mn.us/redcap/surveys/?s=C4LHPRYLXEWDATX3">https://redcap.health.state.mn.us/redcap/surveys/?s=C4LHPRYLXEWDATX3</a>]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Monoclonal Antibody Administration  [<a href="https://redcap.health.state.mn.us/redcap/surveys/?s=8H9YPTACNHTHRT">https://redcap.health.state.mn.us/redcap/surveys/?s=8H9YPTACNHTHRT</a>]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>For facilities that have an existing HPOP account:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Antiviral Product Request Form - Molnupiravir and/or Paxlovid  [<a href="https://redcap.health.state.mn.us/redcap/surveys/?s=MPRFJRDFY4YREDL">https://redcap.health.state.mn.us/redcap/surveys/?s=MPRFJRDFY4YREDL</a>]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Antiviral Product Request Form - Renal Paxlovid  [<a href="https://redcap.health.state.mn.us/redcap/surveys/?s=WJFWAYTW79LCTNW">https://redcap.health.state.mn.us/redcap/surveys/?s=WJFWAYTW79LCTNW</a>]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Antiviral Product Request Form - Evusheld  [<a href="https://redcap.health.state.mn.us/redcap/surveys/?s=TH8FY7AFFWTJL79H">https://redcap.health.state.mn.us/redcap/surveys/?s=TH8FY7AFFWTJL79H</a>]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ mAb Allocation Request Form  [<a href="https://redcap.health.state.mn.us/redcap/surveys/?s=CDK7XH3TC3">https://redcap.health.state.mn.us/redcap/surveys/?s=CDK7XH3TC3</a>] (currently bebtelovimab)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Contact <a href="mailto:Rebecca.Colby.C19@state.mn.us">Rebecca.Colby.C19@state.mn.us</a> or <a href="mailto:Marlee.Etchison@state.mn.us">Marlee.Etchison@state.mn.us</a> with questions about ordering COVID-19 therapeutics from state supply</td>
</tr>
<tr>
<td>Step</td>
<td>Facility requirements</td>
<td>Considerations</td>
<td>Resources and Guidance</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------</td>
<td>----------------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| 5. Get medication to patient | □ Transportation to deliver medications to patient or bring patient to clinic/pharmacy | ▪ Delivery is preferred if health systems or pharmacies offer it. Some clinics will mail prescriptions to patients they see at their clinics. ▪ Keep turnaround time in mind to ensure therapeutics get to patients within the 5-day treatment window for oral antivirals. | Transportation resources  
  ▪ DHS: Nonemergency Medical Transportation (NEMT) Services (www.dhs.state.mn.us/main/id_008991) for Medical Assistance members  
  ▪ Local Public Health  
  ▪ Facilities serving people experiencing homelessness may apply for reimbursement of transportation costs through the MN Interagency Council on Homelessness: Shelter Outbreak Funds (https://mich.mn.gov/shelter-outbreak-funds) |
| 6. Provider follow-up with patient as needed | □ Staff member to coordinate patient follow up with healthcare provider as needed | ▪ In some cases, people treated with Paxlovid may experience a “rebound” of symptoms or a new positive viral test between two and eight days after initial recovery. If rebound occurs, the patient should restart their isolation period and follow usual isolation protocols. | CDC Health Alert Network, COVID-19 Rebound After Paxlovid Treatment (https://emergency.cdc.gov/han/2022/han00467.asp) |